Oxford Global is proud to present the 3rd Annual Oncology Biomarkers Congress which will be held on the 14th & 15th October 2013 at the Hilton Manchester Deansgate, UK. Our esteemed experts will explore the progression of oncology biomarker research from initial discovery through to the development of fully validated companion diagnostics.
Too often, the diagnosis of cancer happens in the late stages of the disease; molecular biomarkers provide a promising prospect for the detection of early stage cancer. On day one, our industry leaders will discuss the latest screening methods, the use of oncology imaging biomarkers and CTCs as PD markers in clinical trials. Our internationally renowned speakers will also assess the latest profiling technologies and their impact on biomarker development.
Following the success of many biomarkers in clinical trials, why are there still very few advances in the development of companion diagnostics? On day two, the discussions will focus on the role of tumour banks in personalised medicine, strategies for the co-development of drug and diagnostics and methods of assay development for the validation of companion diagnostics. Our experts will also discuss the importance of partnering relationships in enhancing the safety and efficacy of personalised medicine.
This two day congress, co-located with our 2nd Annual Oncology Clinical Development Congress 2013 congress is a must for those looking to implement effective biomarker and companion diagnostic strategies.
In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below.
Day 1 – Oncology Biomarkers: Strategies for Successful Discovery, Through to Clinical Translation
- Pre-clinical discovery: PK/PD modelling, target identification, validation & screening
- Early development of safety and toxicity biomarkers
- Case studies of biomarker discovery: proteomic, genomic and metabolomics markers
- Using CTC’s (circulating tumour cells) as PD biomarkers in clinical trials
- Development of new cancer biomarkers from profiling technologies: NMR, Mass Spectroscopy
- The use of non-invasive oncology imaging biomarkers in clinical trials
- Screening methods for the detection of early stage oncology biomarkers
Day 2 – Companion Diagnostics, Patient Selection & Personalised Medicine
- Companion diagnostics development and partnering strategies
- Developing assays for the discovery and validation of companion diagnostics
- Strategies for the drug-diagnostic co-development in oncology
- Patient selection: How can we improve safety and efficacy of new therapies?
- Why so few companion diagnostics? The difficulty of translating biological data into predictive biomarkers
- Tumour banks: the foundations of personalised oncology medicine
Who is speaking
Our carefully researched speaker programmes are further enhanced by the opportunity for the delegates and speakers to discuss topics of interest in more detail during panel and round table discussions. This means that the attendees not only benefit from the expertise of the high level speaker panel but also that of the other delegates.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Arti Pau at email@example.com.
Confirmed 2013 Speakers
- Katia Bassett – Scientist II, Translational Oncology, Geron Corporation
- Nick Crabb – Associate Director - Diagnostics Assessment Programme, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence
- Caroline Dive – Professor, Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research
- Axel Ducret – Principal Scientist, F. Hoffmann-La Roche Ltd
- Pierre Farmer – Principal Scientist, Merck Serono
- Dorothee Foernzler – Principle TransMed Expert Oncology, Boehringer Ingelheim
- Ulf Forssmann – Senior Medical Director, Merck Serono
- Fabien Gaire – Global Head Pathology & Tissue Analytics Oncology DTA, Roche
- Mathias Gebauer – Head Biomarker Identification and Quantification, Sanofi Aventis
- David Henderson – Principal Scientists, Bayer Pharma AG
- Joerg Heyer – Director Cancer Biology, AVEO Oncology
- Heather Keen – Associate Principle Scientist, Astra Zeneca
- Heidi Lane – Head of Cancer Biology, Basilea Pharmaceutica International Ltd
- Rachel Mager – Global Head of Biobanks, Associate Director, AstraZeneca
- Ruth March – VP and Head of Personalised Healthcare and Biomarkers, AstraZeneca
- Christian Meisel – European Head of Translational Medicine, Roche
- Arndt Schmitz – Head of Research Biobank, Clinical Pharmacology-Global Biomarker, Bayer Pharma AG
- Cecilia Schott – Executive Director, AstraZeneca
- Robert Schupp – Executive Director Diagnostics Hematology/Oncology, Celgene Corporation
- Matthew Squires – Global Correlative Science Lead, Director, Oncology Correlative Sciences, Novartis
- Jill Walker – Diagnostic Director, AstraZeneca
Who will attend
The 3rd Annual Oncology Biomarkers Congress is an exclusive event consisting of world-class keynote addresses and panel discussions designed specifically for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Delegates typically include VPs, Directors, Managers and Heads of:
- Biobank Research
- Biomarker Discovery
- Biomarker Validation
- Companion Diagnostics
- Clinical Research
- Clinical Oncology
- Preclinical Safety
- Personalised Medicine
- Statistical Biomarkers
- Translational Research
- Molecular Informatics
- Biomarker Imaging
- Experimental Medicine
- Clinical Discovery
- Systems Biology